The Merck TroFuse 023 and TroFuse 007 studies explore investigational combinations involving MK‑2870 and Pembrolizumab. MK-2870 (sacituzumab tirumotecan) is an investigational antibody-drug conjugate (ADC) being studied for cancer treatment.
The Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center will be conducting the investigation and can provide eligibility information and enrollment guidance for interested patients.
Information from Merck (trial sponsor)
TroFuse 023

TroFuse 007

What is the key difference between these two non-small cell lung cancer trials?
Both trials involve the use of MK-2870. TroFuse 023 adds MK‑2870 after chemotherapy; TroFuse 007 tests MK‑2870 from the start.
TroFuse 023 — After initial treatment
This study looks at MK‑2870 after chemotherapy plus pembrolizumab. Participants first receive standard treatment. The study then compares MK‑2870 + pembrolizumab to pembrolizumab alone to see which approach may help slow or stop the cancer.
TroFuse 007 — As part of first treatment
This study looks at MK‑2870 as part of your first treatment. It compares MK‑2870 + pembrolizumab to pembrolizumab alone to see whether starting with the combination may help slow or stop the cancer.
Principal Investigator

Dr. Wong received his medical degree from USC Keck School of Medicine, before completing his Internal Medicine Residency at the Los Angeles County USC Medical Center. Afterwards, he completed his Hematology-Oncology Fellowship at the UCLA Jonsson Comprehensive Cancer Center. Dr. Wong has authored numerous scientific publications, presented research in international academic meetings, and has participated in professional organizations including the American Society of Hematology and the American Society of Clinical Oncology.
Board Certifications
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Hematology
- American Board of Internal Medicine, Medical Oncology
The Roy and Patricia Disney Family Cancer Center is proud to offer patients access to innovative clinical trials that may help redefine how advanced non-small cell lung cancer is treated. Evaluating MK‑2870 in both first-line and post-chemotherapy settings gives us an opportunity to advance research that could significantly improve the future of lung cancer care.
– Dr. Karlton Tom Wong, MD
What is the trial process like at the Roy and Patricia Disney Family Cancer Center?
When you arrive, you will be warmly welcomed by one of our concierge team members, who will assist you with check-in, answer any initial questions, and guide you to our Hematology/Oncology department.
Before you leave, your care team will provide you with educational materials, discuss the next steps, and schedule any necessary follow-up appointments. If you decide that participating in a clinical trial is right for you, our research team will guide you through the enrollment process and continue to support you throughout your treatment journey. Our goal is to ensure you feel informed, supported, and empowered to make the decisions that are best for you. Thank you for considering us for your care. Our team is committed to providing compassionate, personalized care every step of the way.
Contact the Roy and Patricia Disney Family Cancer Center
For full trial details, eligibility, and enrollment information, please contact the Roy and Patricia Disney Family Cancer Center directly.
Trial Coordinators:
(818) 748-4723
Daisy.Arteaga@providence.org
Sarah Amparado, BSN, RN, OCN
(818)748-4793
Sarah.Amparado@providence.org
Send a message to our trial coordinators:
Providence Roy and Patricia Disney Family Cancer Center
181 S Buena Vista Street
Burbank, CA 91505 (See Google Maps for directions.)
(818) 748-4900
Providence Saint Joseph Medical Center
501 S Buena Vista St, Burbank, CA 91505
Visit Providence.org/locations/socal/Saint-Joseph-Medical-Center.


